… Progress in both areas should advance preclinical assays of novel therapeutics. In that
regard, more progress in establishing patient-derived spheroid, organoid, and xenograft models …

… A similar use of molecular markers is in patients with well … tumor that would be responsive
to platinum-based therapies. … differentiated tumors (panNECs) will guide a change of therapy …

… , overexpress this marker (65) and gastrinomas of the pancreas show low expression …
pancreatic marker. Nuclear positivity for PR has been reported in most pancreatic endocrine tumors…

… be used to study liver metastasis and to test novel therapeutic strategies (74,75). The limitations
… Lastly, improving detection of aggressive tumors by evaluating novel molecular markers …

… Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and
pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase …

… An interesting recent work by Xue and colleagues carried out on 163 resected pancreatic
neuroendocrine tumors establishes the hepatoid variant as one of the most aggressive group …

… There is also hope that the insights gained from such molecular studies may suggest novel
therapeutic approaches, which are also urgently required for PanNEN patients, especially in …

… Integration of high-grade components and molecular markers successfully led to
categorization of 19 out of 20 ambiguous cases [29]. This example highlights the vital need for the …

… incidence of this cancer. In this review, we summarize the state-of-the-art for the treatment
of metastatic PDAC, we explore novel therapies and outline future strategies in development. …

… With the progress in cancer profiling, treatment can now be customized for each individual.
The complexity of microRNA biology may also provide novel therapeutic options for the …